Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
The purpose of this study is to investigate if changes in ocular signs and symptoms occur in
patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005%
(Xalatan) to preservative free Tafluprost eye drops.
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
The objective of this study is to investigate the pharmacodynamics (as expressed in
intraocular pressure [IOP]) of two formulations of tafluprost 0.0015% eyedrops (preserved
and unpreserved) in patients with open-angle glaucoma or ocular hypertension.
The primary aim of this study is to show that IOP reduction between the two formulations is
equivalent at the end of the 4 week treatment period.
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and
Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when
both medications are administered in the evening.
Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)
Merck Sharp & Dohme Corp.
This study was to compare the safety and efficacy of the preservative-free formulation of
0.0015% MK2452 (tafluprost) and preservative-free 0.5% timolol maleate in patients with
open-angle glaucoma and ocular hypertension. This study was to demonstrate that the
preservative-free formulation of 0.0015% tafluprost is non-inferior to preservative-free
0.5% timolol maleate.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.